share_log

CRISPR Therapeutics | 10-K: Annual report

SEC announcement ·  Feb 21 07:55
Summary by Moomoo AI
CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its annual financial report. Financial Performance: The company has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share for the entire year. However, it has recognized $370.0 million in collaboration revenue for the year ended December 31, 2023, primarily related to agreements with Vertex Pharmaceuticals. Additionally, grant revenue amounted to $1.2 million. Business Development: CRISPR Therapeutics has made strides in its business development, with the landmark approval of CASGEVY, the world's first CRISPR-based gene-editing therapy, for the treatment of severe SCD or TDT. The company has also advanced multiple gene-edited cell therapy programs for oncology and autoimmune diseases, and initiated Phase 1 clinical trials for...Show More
CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its annual financial report. Financial Performance: The company has not disclosed specific revenue, operating profit, net profit, or diluted earnings per share for the entire year. However, it has recognized $370.0 million in collaboration revenue for the year ended December 31, 2023, primarily related to agreements with Vertex Pharmaceuticals. Additionally, grant revenue amounted to $1.2 million. Business Development: CRISPR Therapeutics has made strides in its business development, with the landmark approval of CASGEVY, the world's first CRISPR-based gene-editing therapy, for the treatment of severe SCD or TDT. The company has also advanced multiple gene-edited cell therapy programs for oncology and autoimmune diseases, and initiated Phase 1 clinical trials for in vivo gene editing programs targeting cardiovascular disease. Future Plans: The company plans to continue expanding its clinical trials, including initiating a trial for CTX112 in systemic lupus erythematosus and expanding trials of CTX131 into hematologic malignancies. It also aims to advance its portfolio of in vivo programs and develop gene-edited stem cell-derived therapies for the treatment of Type 1 Diabetes. CRISPR Therapeutics is focused on innovating next-generation editing modalities through its CRISPR-X research team and establishing internal manufacturing capabilities for clinical and commercial production of its product candidates.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Doc 7

Doc 8

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more